Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 16/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984523 | 0.90 | AOC3 (0.64) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL6259378 | 0.85 | AOC3 (0.58) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL5550389 | 0.84 | AOC3 (0.60) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL5545486 | 0.83 | AOC3 (0.53) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3932277 | 0.81 | AOC3 (0.64) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3939157 | 0.81 | AOC3 (0.78) | AOC3MAOBSMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL3936446 | 0.80 | AOC3 (0.76) | AOC3MAOBSMN1; SMN2KMT2A | |
| SCHEMBL5504215 | 0.80 | AOC3 (0.51) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL4865974 | 0.79 | AOC3 (0.58) | AOC3MAOBSMN1; SMN2KMT2ANPC1 | |
| SCHEMBL3934843 | 0.79 | AOC3 (0.60) | AOC3MAOBSMN1; SMN2KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 386/4885MAOB 3666/4885SMN1; SMN2 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.